$3.09
1.90%
Nasdaq, Oct 01, 04:00 pm EDT. Closed.
ISIN
US52886N4060
Symbol
LEXX

Lexaria Bioscience Corp Stock price

$3.09
-9.39 75.23% 1M
-9.90 76.22% 6M
-6.17 66.61% YTD
-11.54 78.88% 1Y
-11.39 78.65% 3Y
-92.61 96.77% 5Y
-53.07 94.50% 10Y
-160.55 98.11% 20Y
Nasdaq, Closing price Thu, Oct 01 2026
-0.06 1.90%
ISIN
US52886N4060
Symbol
LEXX
Industry

Is Lexaria Bioscience Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$6.6m
Enterprise Value
$3.0m
Net debt
positive
Cash
$3.6m
Shares outstanding
1.7m
Valuation (TTM | estimate)
P/E
negative
P/S
34.9 | 325.5
EV/Sales
15.9 | 148.0
EV/FCF
negative
P/B
1.4
Financial Health
Equity Ratio
71.6%
Return on Equity
-398.1%
ROCE
-175.2%
ROIC
-470.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$190.0k | $20.4k
EBITDA
$-7.6m
EBIT
$-7.7m
Net Income
$-7.7m
Free Cash Flow
$-7.7m
Growth (TTM | estimate)
Revenue
-69.4% | -97.1%
EBITDA
32.5%
EBIT
32.4%
Net Income
32.1%
Free Cash Flow
22.1%
Margin
Gross
100.0%
EBITDA
-3,933.7%
EBIT
-3,973.1%
Net
-3,985.6%
Free Cash Flow
-3,953.9%
More
EPS
$-4.7
FCF per Share
$-4.6
Short interest
8.8%
Employees
7
Rev per Employee
$100.0k

Lexaria Bioscience Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Lexaria Bioscience Corp forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Lexaria Bioscience Corp forecast:

Buy
86%
Hold
14%

Financial data from Lexaria Bioscience Corp

May '26
+/-
%
0.19 0.19
69% 69%
100%
- Direct Costs - -
-
-
0.19 0.19
69% 69%
100%
- Selling and Administrative Expenses 3.90 3.90
17% 17%
2,053%
- Research and Development Expense 4 4
45% 45%
2,105%
-7.63 -7.63
33% 33%
-4,016%
- Depreciation and Amortization 0.08 0.08
11% 11%
42%
EBIT (Operating Income) EBIT -7.71 -7.71
32% 32%
-4,057%
Net Profit -7.73 -7.73
32% 32%
-4,068%

In millions USD.

Don't miss a Thing! We will send you all news about Lexaria Bioscience Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lexaria Bioscience Corp Stock News

Neutral
Accesswire
●
14 days ago
KELOWNA, BC / ACCESS Newswire / September 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update. Lexaria is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at US$12.92/share.
Neutral
Accesswire
●
22 days ago
KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exe...
Neutral
Accesswire
●
about one month ago
Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated Findings support Lexaria's expanding strategic partnering outreach activities ...
More Lexaria Bioscience Corp News

Company Profile

Lexaria Bioscience Corp. is a proprietary drug delivery technology company. Its technology DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption, reduces time of onset, and masks unwanted tastes for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products; and to a tobacco producer for the development of smokeless, oral-based nicotine products. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Head office United States
CEO Mr. Christopher
Employees 7
Founded 2004
Website www.lexariabioscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today